GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.

doi:10.1097/MD.0000000000003487

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.

Medicine - 1 Apr 2016

Lin Wey-Ran, Chiang Jy-Ming, Liang Kung-Hao, Lim Siew-Na, Lai Ming-Wei, Tsou Yung-Kuan, Hsieh Tzu-Yun, Hsu Chih-Kai, Yeh Chau-Ting

Abstract excerpt

Adjuvant oxaliplatin-based chemotherapy is widely used for stage III colorectal cancer (CRC) after curative surgery. CRC is a molecularly heterogeneous disease, and our current knowledge of therapeutic response-related genetic factors remains limited. N-acetylgalactosaminyltransferase 14 (GALNT14)-rs9679162 genotype is a prognostic predictor for chemotherapy response in advanced hepatocellular carcinoma. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Colectomy

Share to Deoxycytidine

Share to Leucovorin

Share to N-Acetylgalactosaminyltransferases

Share to Organoplatinum Compounds

Share to Oxaliplatin

Source

Open in PubMed Open full text

Identifiers

PMID: 27124048
DOI: 10.1097/MD.0000000000003487
PMCID: PMC4998711

Genes

GALNT14

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.PMID 27124048Read ↗

A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.Semantic proximity Read ↗

Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma.Semantic proximity Read ↗

Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.Semantic proximity Read ↗

An SNP Marker Predicts Colorectal Cancer Outcomes with 5-Fluorouracil-Based Adjuvant Chemotherapy Post-Resection.Semantic proximity Read ↗

GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.Semantic proximity Read ↗

GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.Semantic proximity Read ↗

[The influence of XRCC1 gene polymorphism on the prognosis and safety of stage Ⅲ patients with colorectal cancer who received oxaliplatin based adjuvant chemotherapy].Semantic proximity Read ↗

Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer.Semantic proximity Read ↗

GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers.Semantic proximity Read ↗

The Impact of GST Genetic Polymorphisms on the Response to Oxaliplatin-Based Chemotherapy and Survival Prognosis in Gastric Cancer PatientsSemantic proximity Read ↗

ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.Semantic proximity Read ↗

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.